论文部分内容阅读
目的观察吡格列酮对2型糖尿病患者骨转换生化指标的影响。方法比较70例2型糖尿病患者加用吡格列酮治疗12周前后血清Ⅰ型原胶原N末端前肽(PINP)、总碱性磷酸酶(T-ALP)、骨钙素(OC)、Ⅰ型胶原交联C末端肽(CTX)等骨转化指标的变化。结果吡格列酮治疗12周后,2型糖尿病患者血清PINP和T-ALP水平较治疗前明显降低(P<0.01),并且这种下降作用主要来源于女性亚组的贡献。OC和CTX在治疗前后无明显变化。结论吡格列酮可抑制骨形成,而对骨吸收则可能无明显影响,提示吡格列酮对2型糖尿病患者骨转换的影响主要是抑制骨形成。
Objective To observe the effect of pioglitazone on biochemical markers of bone turnover in type 2 diabetic patients. Methods Seventy patients with type 2 diabetes were treated with pioglitazone for 12 weeks before and after treatment. The serum levels of type Ⅰ procollagen (PINP), total alkaline phosphatase (T-ALP), osteocalcin (OC) and type Ⅰ collagen C-terminal peptide (CTX) and other changes in bone turnover indicators. Results After 12 weeks pioglitazone treatment, serum PINP and T-ALP levels were significantly lower in patients with type 2 diabetes than those before treatment (P <0.01), and this decline mainly came from the contribution of the female subgroup. OC and CTX did not change significantly before and after treatment. Conclusion Pioglitazone can inhibit bone formation, but may not affect bone resorption, suggesting that the effect of pioglitazone on type 2 diabetes patients with bone turnover is mainly to inhibit bone formation.